Clovis Oncology, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Boulder, CO
SEC filing record 1 source field available
Fiscal year end
31 December
Clovis Oncology, Inc. has filed 952 SEC EDGAR filings since 25 Jun 2009

SEC filing history

Showing 501-525 of 951 matching filings.

Per page
25
Current page
21
4

FORM 4 SUBMISSION

Filing date
16 Feb 2018
Reporting date
15 Feb 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

SC 13G/A filing

Filing date
14 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

SCHEDULE 13G/A

Filing date
14 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

AMENDMENT NO. 3

Filing date
14 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

CONSONANCE CAPITAL MANAGEMENT LP

Filing date
14 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

SC 13G/A filing

Filing date
13 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

SC 13G/A filing

Filing date
09 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

SC 13G/A filing

Filing date
08 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-86488

SC 13G filing

Filing date
06 Feb 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-86488

SC 13G/A filing

Filing date
30 Jan 2018
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Jan 2018
Reporting date
16 Jan 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
09 Jan 2018
Reporting date
08 Jan 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
21 Dec 2017
Reporting date
20 Dec 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
21 Dec 2017
Reporting date
20 Dec 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
18 Dec 2017
Reporting date
15 Dec 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
08 Dec 2017
Reporting date
08 Dec 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
01 Dec 2017
Reporting date
29 Nov 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
01 Dec 2017
Reporting date
29 Nov 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Nov 2017
Reporting date
15 Nov 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-35347

FORM 8-K

Filing date
02 Nov 2017
Reporting date
02 Nov 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-35347

CLOVIS ONCOLOGY, INC. 8-K

Filing date
01 Nov 2017
Reporting date
01 Nov 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
17 Oct 2017
Reporting date
16 Oct 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
18 Sep 2017
Reporting date
15 Sep 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4/A

FORM 4/A SUBMISSION

Filing date
01 Sep 2017
Reporting date
29 Aug 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .